Rani Therapeutics Holdings (RANI) Net Equity Issued and Repurchased (2024 - 2025)
Rani Therapeutics Holdings (RANI) posted Net Equity Issued and Repurchased of $47.0 million for Q4 2025, up 1571.18% on a QoQ basis from $2.8 million in Q3 2025, and up 9371.17% year-over-year from $496000.0 in Q4 2024.
Powered by 
Analysis
Rani Therapeutics Holdings (RANI) Net Equity Issued and Repurchased (2024 - 2025) Analysis & Trends
Rani Therapeutics Holdings has reported Net Equity Issued and Repurchased for 2 years, with the latest figure at $47.0 million in Q4 2025.
- On a quarterly basis, Net Equity Issued and Repurchased rose 9371.17% year-over-year to $47.0 million in Q4 2025; TTM through Dec 2025 was $50.3 million, a N/A change from a year earlier, with the FY2025 full-year figure at $49.8 million, up 430.85% from the prior year.
- Net Equity Issued and Repurchased was $47.0 million for Q4 2025 at Rani Therapeutics Holdings, up from $2.8 million in the prior quarter.
- The five-year high for Net Equity Issued and Repurchased was $47.0 million in Q4 2025, with the low at $496000.0 in Q4 2024.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Equity Issued and Repurchased (Qtr) |
|---|---|---|---|---|---|
| 1 | Amgen | 203.97 Bn | 189.99 Bn | 7.24 Bn | - |
| 2 | Gilead Sciences | 178.74 Bn | 175.56 Bn | 6.22 Bn | 9.00 Mn |
| 3 | Vertex Pharmaceuticals | 130.73 Bn | 122.88 Bn | 2.84 Bn | - |
| 4 | Regeneron Pharmaceuticals | 80.42 Bn | 72.42 Bn | 3.93 Bn | 49.20 Mn |
| 5 | Argenx Se | 60.40 Bn | 55.21 Bn | 1.37 Bn | - |
| 6 | Moderna | 57.65 Bn | 52.52 Bn | 52.00 Mn | - |
| 7 | Alnylam Pharmaceuticals | 33.37 Bn | 30.07 Bn | 992.69 Mn | - |
| 8 | Biogen | 32.15 Bn | 30.86 Bn | 1.96 Bn | - |
| 9 | Roivant Sciences | 29.58 Bn | 29.58 Bn | 1.16 Mn | - |
| 10 | Rani Therapeutics Holdings | 157.97 Mn | 157.97 Mn | - | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Dec 31, 2025 | 46.98 Mn |
| Sep 30, 2025 | 2.81 Mn |
| Dec 31, 2024 | 496,000.00 |